Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Nivolumab has clinical activity in a subset of patients with mCRPC; however, DRD does not predict response. These results highlight the necessity of identifying new biomarkers to more accurately determine patients with mCRPC who might respond to ICIs.
Authors
- Pedro Isaacsson Velho (ORCID: https://orcid.org/0000-0002-3117-7031)
- Maria Aparecida Azevedo Koike Folgueira (ORCID: https://orcid.org/0000-0001-9269-8052)
- Maria Lúcia Hirata Katayama (ORCID: https://orcid.org/0000-0002-2672-8222)
- Diogo Assed Bastos (ORCID: https://orcid.org/0000-0003-2480-353X)
- Luana Giongo Pedrotti (ORCID: https://orcid.org/0000-0001-9755-9019)
- David Queiroz Borges Muniz (ORCID: https://orcid.org/0000-0003-0661-7960)
- Rafael Dal Ponte Ferreira (ORCID: https://orcid.org/0000-0001-5910-1808)
- Emily Tonin da Costa (ORCID: https://orcid.org/0000-0003-0899-1454)
- Alessandro Leal (ORCID: https://orcid.org/0000-0001-7967-3213)
- Simone Maistro (ORCID: https://orcid.org/0000-0002-0937-2391)
- Brenda Rigatti (ORCID: https://orcid.org/0000-0002-4359-3673)
- Alessandra Morelle (ORCID: https://orcid.org/0000-0002-0744-4523)
- Gilberto de Castro (ORCID: https://orcid.org/0000-0001-8765-3044)
- Felipe Andreis
- Pedro Tofani. Saint'ana
Institutions
- Johns Hopkins University (US)
- Hospital Moinhos de Vento (BR)
- Instituto do Câncer do Estado de São Paulo (BR)
- Precision for Medicine (United States) (US)
- Hospital São Lucas da PUCRS (BR)
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
- Hospital Sírio-Libanês (BR)
- University of Baltimore (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1595
- Citations
- 13
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.67